This study combined evidence from a nationwide population-based cohort study and a study using MR study design to provide more robust causal inferences between the use of GLP-1 RAs and the risk of DR in patients with type 2 diabetes mellitus. This evidence concerns the gene GCG and diabetes mellitus.